ArticlePeerJ2026
Status of financial toxicity and its influence on quality of life in patients with gynecological malignancies in China.
Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gynecological malignancies impose a substantial health and economic burden in China. The high cost of treatment often results in considerable financial toxicity, placing economic strain on patients and their families. These challenges can reduce treatment adherence, heighten emotional distress, and impair quality of life. This study aims to assess the degree of financial toxicity among patients with gynecological cancers, evaluate its impact on quality of life, and provide evidence to support the development of targeted clinical interventions to mitigate its adverse effects. Methods: A convenience sampling approach was employed to recruit 281 patients with gynecological malignancies from two hospitals in Nanjing. A cross-sectional survey was conducted between November 2022 and December 2024. Data were collected using general information questionnaires, the financial toxicity comprehensive scale, and the cancer patient quality-of-life assessment scale. Results: Data validity was confirmed using Harman's single-factor test (first factor explanatory rate was 30.44%). The mean ± SD total financial toxicity score of the patients was 20.80 ± 7.32 points, with 73% (205/281) experiencing significant financial burdens. The financial resource dimension had the lowest mean score 3.40 ± 1.37 points. Multivariate linear regression analysis indicated that the age of children, family per capita monthly income, treatment costs in the past three months, and marital status were the core influencing factors (adjusted Conclusion: The majority of studied patients experienced financial toxicity, with financial status, family dynamics, and widowhood being key influencing factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.